Effect of stereoisomerism on the cellular pharmacology of beta-enantiomers of cytidine analogs in Hep-G2 cells

被引:16
作者
Martin, LT
Faraj, A
Schinazi, RF
Gosselin, G
Mathe, C
Imbach, JL
Sommadossi, JP
机构
[1] UNIV ALABAMA, DEPT PHARMACOL & TOXICOL, DIV CLIN PHARMACOL, CTR LIVER, BIRMINGHAM, AL 35294 USA
[2] VET AFFAIRS MED CTR, GEORGIA VA RES CTR AIDS & HIV INFECT, DECATUR, GA 30033 USA
[3] EMORY UNIV, SCH MED, DEPT PEDIAT, BIOCHEM PHARMACOL LAB, ATLANTA, GA 30322 USA
[4] UNIV MONTPELLIER 2, BIOORGAN CHEM LAB, UMR 5625, CNRS, F-34095 MONTPELLIER, FRANCE
关键词
nucleoside analog; stereoisomer; enantioselective; metabolism; antiviral;
D O I
10.1016/S0006-2952(96)00653-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The beta-L enantiomers of 2',3'-dideoxycytidine (beta-L-ddC) and its 5-fluoro derivative, 2',3'-dideoxy-5-fluorocytidine (beta-L-FddC), were demonstrated to be active against human immunodeficiency virus (HIV) and hepatitis B virus (HBV) replication in vitro. In the present study, we investigated the cellular pharmacology of beta-L-ddC and beta-L-FddC and compared it with that of beta-D-2',3'-dideoxy-5-fluorocytidine (beta-D-FddC). beta-L-FddC (10 mu M) was found to be phosphorylated rapidly in Hep-G2 cells to its 5'-mono-, di-, and triphosphate derivatives with intracellular triphosphate levels achieving 26.6 +/- 10.9 pmol/10(6) cells after 72 hr. In contrast, the active 5'-phosphorylated derivative of beta-D-FddC achieved lower levels with triphosphate levels of only 23 +/- 0.5 pmol/10(6) cells under the same conditions. beta-L-ddC was also phosphorylated rapidly. A 5'-diphosphocholine (18.7 +/- 5.8 pmol/10(6) cells) and a 5'-diphosphoethanolamine (13.6 +/- 0.9 pmol/10(6) cells) derivative were detected in beta-D-FddC-treated cells after 72 hr, whereas in beta-L-FddC- and beta-L-ddC-treated cells, only the 5'-diphosphocholine derivative (10.9 +/- 2.8 and 60.4 +/- 5.7 pmol/10(6) cells, respectively) was detected. beta-L-FddC-5'-triphosphate (beta-L-FddCTP), beta-D-FddC-5'-triphosphate (beta-D-FddCTP), and beta-L-ddC-5'-triphosphate (beta-L-ddCTP) followed a single phase elimination process with an intracellular half-life (T-1/2) of 10.5, 5.7, and 12.3 hr, respectively. Furthermore, beta-L-FddCTP, beta-D-FddCTP, and beta-L-ddCTP levels of 6.7 +/- 2.3, 0.3 +/- 0.1, and 12.0 pmol/10(6) cells, respectively, were still detectable 24 hr following drug removal. The higher intracellular 5'-triphosphate levels of beta-L-FddC and the extended T-1/2 of its 5'-triphosphate are consistent with the more potent in vitro antiviral activity of beta-L-FddC in Hep-G2 cells when compared with its beta-D enantiomer, beta-D-FddC. Copyright (C) 1996 Elsevier Science Inc.
引用
收藏
页码:75 / 87
页数:13
相关论文
共 37 条
[1]  
ADUMA P, 1995, MOL PHARMACOL, V47, P816
[2]   DEOXYCYTIDINE AND 2',3'-DIDEOXYCYTIDINE METABOLISM IN HUMAN MONOCYTE-DERIVED MACROPHAGES A STUDY OF BOTH ANABOLIC AND CATABOLIC PATHWAYS [J].
ARNER, ESJ ;
ERIKSSON, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 197 (03) :1499-1504
[3]   CELLULAR-METABOLISM OF (-) ENANTIOMERIC 2'-DEOXY-3'-THIACYTIDINE [J].
CAMMACK, N ;
ROUSE, P ;
MARR, CLP ;
REID, PJ ;
BOEHME, RE ;
COATES, JAV ;
PENN, CR ;
CAMERON, JM .
BIOCHEMICAL PHARMACOLOGY, 1992, 43 (10) :2059-2064
[4]  
CHANG CN, 1992, J BIOL CHEM, V267, P13938
[5]   THE SEPARATED ENANTIOMERS OF 2'-DEOXY-3'-THIACYTIDINE (BCH-189) BOTH INHIBIT HUMAN-IMMUNODEFICIENCY-VIRUS REPLICATION INVITRO [J].
COATES, JAV ;
CAMMACK, N ;
JENKINSON, HJ ;
MUTTON, IM ;
PEARSON, BA ;
STORER, R ;
CAMERON, JM ;
PENN, CR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (01) :202-205
[6]   (-)-Cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine (524W91) inhibits hepatitis B virus replication in primary human hepatocytes [J].
Condreay, LD ;
Condreay, JP ;
Jansen, RW ;
Paff, MT ;
Averett, DR .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (02) :520-523
[7]   FRESHLY ISOLATED OR CRYOPRESERVED HUMAN HEPATOCYTES IN PRIMARY CULTURE - INFLUENCE OF DRUG-METABOLISM ON HEPATOTOXICITY [J].
DESOUSA, G ;
DOU, M ;
BARBE, D ;
LACARELLE, B ;
PLACIDI, M ;
RAHMANI, R .
TOXICOLOGY IN VITRO, 1991, 5 (5-6) :483-486
[8]   A PRELIMINARY TRIAL OF LAMIVUDINE FOR CHRONIC HEPATITIS-B INFECTION [J].
DIENSTAG, JL ;
PERRILLO, RP ;
SCHIFF, ER ;
BARTHOLOMEW, M ;
VICARY, C ;
RUBIN, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (25) :1657-1661
[9]   INHIBITION OF THE REPLICATION OF HEPATITIS-B VIRUS INVITRO BY 2',3'-DIDEOXY-3'-THIACYTIDINE AND RELATED ANALOGS [J].
DOONG, SL ;
TSAI, CH ;
SCHINAZI, RF ;
LIOTTA, DC ;
CHENG, YC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (19) :8495-8499
[10]   TREATMENT WITH LAMIVUDINE, ZIDOVUDINE, OR BOTH IN HIV-POSITIVE PATIENTS WITH 200 TO 500 CD4+ CELLS PER CUBIC MILLIMETER [J].
ERON, JJ ;
BENOIT, SL ;
JEMSEK, J ;
MACARTHUR, RD ;
SANTANA, J ;
QUINN, JB ;
KURITZKES, DR ;
FALLON, MA ;
RUBIN, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (25) :1662-1669